Naonobu Sugiyama
Shibuya, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Comparative Safety Analysis of Targeted Synthetic and Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis: A Nationwide Cohort Study in Japan.
Journal: International journal of rheumatic diseases
Published: March 20, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.
Journal: Rheumatology and therapy
Published: September 06, 2025
Incidence and Risk of Malignancy in Japanese Patients With Rheumatoid Arthritis in the National Database of Rheumatic Diseases in Japan (NinJa Database).
Journal: International journal of rheumatic diseases
Published: February 14, 2025
Three-year safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Final analysis of an all-case postmarketing surveillance study.
Journal: Modern rheumatology
Published: December 18, 2024
Risk Factors Associated With Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis in a Real-World Setting in Japan.
Journal: International journal of rheumatic diseases
Published: August 23, 2024
Methotrexate, Tofacitinib, and Biologic Disease-Modifying Antirheumatic Drug Safety and Effectiveness Among Patients with Rheumatoid Arthritis in Japan: CorEvitas Registry Observational Study.
Journal: Rheumatology and therapy
Published: April 20, 2024
Incidence of Malignancies and the Association with Biological Disease-Modifying Antirheumatic Drugs in Japanese Patients with Rheumatoid Arthritis: A Time-Dependent Analysis from the IORRA Patient Registry.
Journal: Rheumatology and therapy
Published: February 22, 2024
Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis.
Journal: Frontiers in immunology
Published: January 28, 2024
Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Journal: Modern rheumatology
Published: March 07, 2023
Validity of claims-based diagnoses for infectious diseases common among immunocompromised patients in Japan.
Journal: BMC infectious diseases
Published: December 21, 2022
Validation of claims-based algorithms for rheumatoid arthritis in Japan: Results from the VALIDATE-J study.
Journal: International journal of rheumatic diseases
Published: September 06, 2022
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Journal: Annals of the rheumatic diseases
Published: March 25, 2022
Last Updated: 09/26/2026